Justin M. Balko
Vanderbilt University Medical Center
232 Papers
531 Citations
Justin M. Balko is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 54, co-authored 172 publications. Previous affiliations of Justin M. Balko include The Breast Cancer Research Foundation & Vanderbilt University.
Chat about Author
Papers
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
Derek A. Franklin,Joe T. Sharick,Joe T. Sharick,Paula I. Ericsson-Gonzalez,Violeta Sanchez,Phillip T. Dean,Susan R. Opalenik,Stefano Cairo,Jean Gabriel Judde,Michael T. Lewis,Jenny C. Chang,Melinda E. Sanders,Rebecca S. Cook,Melissa C. Skala,Jennifer Bordeaux,Jehovana Orozco Bender,Christine Vaupel,Gary K. Geiss,Douglas Hinerfeld,Justin M. Balko,Justin M. Balko +20 more
TL;DR: Molecular studies of paired TNBC patient–derived xenografts (PDXs) established before and after the development of chemoresistance suggest that Ras/MAPK pathway inhibitors may be effective in some breast cancer patients to reverse Ras/ MAPK-driven tumor metabolism and immunosuppression, particularly in the setting of Chemoresistance.
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer
Rinath Jeselsohn,Roman Yelensky,Gilles Buchwalter,Gilles Buchwalter,Garrett M. Frampton,Funda Meric-Bernstam,Ana M. Gonzalez-Angulo,Jaime Ferrer-Lozano,Jose Alejandro Perez-Fidalgo,Massimo Cristofanilli,Henry L. Gomez,Carlos L. Arteaga,Jennifer M. Giltnane,Justin M. Balko,Maureen T. Cronin,Mirna Jarosz,James Sun,Matthew J. Hawryluk,Doron Lipson,Geoff Otto,Jeffrey S. Ross,Addie Dvir,Lior Soussan-Gutman,Ido Wolf,Tamar Rubinek,Lauren Gilmore,Stuart J. Schnitt,Steven E. Come,Lajos Pusztai,Philip J. Stephens,Myles Brown,Myles Brown,Vincent A. Miller +32 more
TL;DR: Functional studies in cell line models demonstrate that functional ESR1 mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments during the progression of ER+ breast cancer.
Corticosteroids and Cancer Immunotherapy.
TL;DR: In this paper , the effect of systemic steroids on immunotherapy efficacy remains somewhat conflicted and unclear, and recent advances in the knowledge of their impact on ICI efficacy in unique populations and settings, associated precautions, and steroid-sparing treatment approaches are reviewed.
Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer
Jennifer B. Dennison,Jennifer R. Molina,Shreya Mitra,Ana M. Gonzalez-Angulo,Justin M. Balko,Maria G. Kuba,Melinda E. Sanders,Joseph A. Pinto,Henry L. Gomez,Carlos L. Arteaga,Robert E. Brown,Gordon B. Mills +11 more
TL;DR: In this paper, metabolic genes were evaluated in vitro for the highest scoring metabolic gene, lactate dehydrogenase B (LDHB ), and its expression was associated with response to neoadjuvant chemotherapy response and relapse within clinical and PAM50-derived subtypes.
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma.
Carlos A. Morales-Betanzos,Hyoung Joo Lee,Paula Gonzalez Ericsson,Justin M. Balko,Douglas B. Johnson,Lisa J. Zimmerman,Daniel C. Liebler +6 more
TL;DR: Targeted MS can provide a next-generation analysis platform to advance cancer immuno-therapeutic research and diagnostics and suggest that N-glycosylation may affect IHC measurement and PD-L1 function.